News Sentiment

NBP sentiment intelligence

NovaBridge Biosciences news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.78 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-6.3% over one week, +18.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

NovaBridge Biosciences (NBP) Holds Near Support Amid Modest Pullback - Combination Correction

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction -6.3% Price reacting lower
Trend fit Trend inactive 18.7% over four weeks
Fair value -14.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 35
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
Market source 6
simplywall.st 6
TradingView 5
GlobeNewswire 4
TradingKey 3
dars.gov.et 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 11
Deals and strategy 2
Analyst action 1
Regulatory and legal 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
The Globe and Mail Direct company coverage

NovaBridge Biosciences Launches 2026 Omnibus Share Incentive Plan

NovaBridge Biosciences has launched a new 2026 Omnibus Share Incentive Plan, replacing previous equity compensation schemes with a single framework. The plan authorizes the issuance of up to 11,960,000 ordinary shares initially and aims to attract and retain talent through stock

Tone
Neutral 50/100
Event
Market update
Published
18 Jul 2026 10:41
Source
The Globe and Mail
Stock Titan Direct company coverage

NovaBridge Biosciences (NBP) sets 2026 equity plan with 11.96M shares

NovaBridge Biosciences has established a new 2026 Omnibus Share Incentive Plan, effective July 13, 2026, which initially reserves up to 11.96 million ordinary shares (equivalent to 5.2 million American Depositary Shares). The plan succeeds previous incentive plans and includes an

Tone
Positive 62/100
Event
Market update
Published
17 Jul 2026 10:09
Source
Stock Titan
Stock Titan Direct company coverage

NovaBridge Biosciences (NBP) awards 949,050 long-dated stock options to its CCO

NovaBridge Biosciences (NBP) has awarded its Chief Commercial Officer, Mark Arnold Hagler, 949,050 employee share options. These options, exercisable for American Depositary Shares (ADS) at $1.93 per ADS, vest in four equal annual installments starting April 17, 2027, and expire

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

NovaBridge Biosciences (NBP) awards 254,780 employee share options to General Counsel

NovaBridge Biosciences (NBP) has granted its General Counsel, Lin Liwei Lorraine, 254,780 2025 Employee Share Options. These options, with an exercise price of $1.93 per American Depositary Share (ADS), will vest over five years, with an initial 40% vesting on February 1, 2026, a

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:40
Source
Stock Titan
Fierce Biotech Direct company coverage

Idorsia locks in new CEO after shakeup—Chutes & Ladders

Idorsia has appointed Roland Wandeler as its new CEO, effective October 1, following the departure of former chief Srishti Gupta. Gupta, who left Idorsia in March, has since been named CEO of NovaBridge BioSciences. Additionally, Muna Therapeutics has brought in Michel Detheux as

Tone
Positive 67/100
Event
Market update
Published
10 Jul 2026 12:39
Source
Fierce Biotech
Stock Titan Direct company coverage

NovaBridge (NBP) CEO awarded 3M options vesting over four years

NovaBridge Biosciences' CEO, Srishti Gupta, was granted 3,000,000 employee share options with an exercise price of $2.01 per ADS-equivalent. These options will vest in four equal annual installments starting on July 1, 2026, and will expire on July 6, 2036. This grant serves as a

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Stock Titan
Stock Titan Direct company coverage

NovaBridge Biosciences (NBP) CEO Srishti Gupta files initial insider ownership statement

NovaBridge Biosciences CEO Srishti Gupta has filed an initial statement of beneficial ownership (Form 3) as an insider of the company. The filing indicates her role as Director and Chief Executive Officer but reports no equity transactions, derivative positions, or reportable hol

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:40
Source
Stock Titan
Investing.com Direct company coverage

NovaBridge Biosciences SVP sells $3,991 in ordinary shares

NovaBridge Biosciences Senior Vice President of Clinical Development, Xu Cong Claire, sold 4,485 ordinary shares for $3,991. This transaction followed her acquisition of 12,432 ordinary shares through vested restricted share units. The company has also recently received Fast Trac

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 00:10
Source
Investing.com
Stock Titan Direct company coverage

NovaBridge Biosciences (NBP) SVP exercises RSUs and sells Ordinary Shares in Form 4 filing

Xu Cong Claire, SVP, Clinical Development at NovaBridge Biosciences (NBP), reported exercising Restricted Share Units (RSUs) and selling Ordinary Shares. On July 4, 2026, she converted 5,405 RSUs, equivalent to 5,405 American Depositary Shares (ADSs), into 12,432 Ordinary Shares.

Tone
Negative 39/100
Event
Market update
Published
08 Jul 2026 00:10
Source
Stock Titan
Seeking Alpha Direct company coverage

NovaBridge: Rebranded, Repackaged, But Far From De-Risked (NASDAQ:NBP)

NovaBridge (NBP), formerly I-Mab, has been rebranded but still faces significant risks, leading to a Sell rating. The lead asset, givastomig, has limited market opportunity, intense competition, and is only 50% owned by NBP. The company's high cash burn and negative risk-adjusted

Tone
Negative 26/100
Event
Analyst action
Published
04 Jul 2026 15:54
Source
Seeking Alpha
Finviz Direct company coverage

NBP - NovaBridge Biosciences ADR Latest SEC Filings

This article provides the latest SEC filings for NovaBridge Biosciences ADR (NBP), including key financial data, stock performance metrics, and insider/institutional ownership details. As of July 2, the stock closed at $2.14, up 7.54%, with a market cap of $246.91 million. The fi

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 16:12
Source
Finviz
富途牛牛 Direct company coverage

Reversal Of Fortune For NovaBridge Biosciences Insiders Who Made A US$5.09m Purchase

This article analyzes recent insider buying activity at NovaBridge Biosciences. Despite a significant US$5.09 million purchase by insiders over the last year, the stock has dropped 15%, suggesting a potential "reversal of fortune." The article emphasizes that while insider buying

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 16:12
Source
富途牛牛
Stock Titan Direct company coverage

Fu Wei at NovaBridge (NBP) awarded RSUs and long-dated options

NovaBridge Biosciences director Fu Wei has been awarded significant equity compensation, including 1,010,100 Restricted Share Units (RSUs) and three tranches of 2025 Employee Share Options. The RSUs vest over two years in equal annual installments starting June 29, 2027, while th

Tone
Positive 62/100
Event
Market update
Published
01 Jul 2026 03:10
Source
Stock Titan
www.marketscreener.com Direct company coverage

Novabridge Biosciences Announces Appointment of Srishti Gupta as Member of the Board of Directors, Effective July 1, 2026

Novabridge Biosciences has announced the appointment of Dr. Srishti Gupta to its Board of Directors, effective July 1, 2026. Dr. Gupta brings over two decades of leadership experience in biopharmaceuticals, global health, and strategy, including her recent role as CEO of Idorsia

Tone
Positive 73/100
Event
Market update
Published
30 Jun 2026 03:10
Source
www.marketscreener.com
MSN Direct company coverage

NovaBridge Biosciences appoints Srishti Gupta as CEO

NovaBridge Biosciences has announced the appointment of Srishti Gupta as its new Chief Executive Officer. This leadership change is expected to guide the company's strategic direction and innovation in the biosciences sector. Gupta's appointment signals a new chapter for NovaBrid

Tone
Positive 71/100
Event
Market update
Published
29 Jun 2026 14:09
Source
MSN
GuruFocus Direct company coverage

NovaBridge Biosciences (NBP) Appoints Srishti Gupta as New CEO

NovaBridge Biosciences (NBP) has appointed Srishti Gupta as its new CEO and board member, effective July 1, 2026. Gupta's appointment is expected to drive the company's strategic objectives, particularly in advancing its oncology pipeline with givastomig and exploring new partner

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 12:41
Source
GuruFocus
citybiz Direct company coverage

NovaBridge Biosciences Names Dr. Srishti Gupta CEO to Lead Clinical Development Strategy

NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new CEO, effective July 1, 2026, to steer the company's clinical development strategy and foster strategic partnerships. Dr. Gupta will focus on advancing lead oncology candidate givastomig towards regulatory registrat

Tone
Positive 77/100
Event
Regulatory and legal
Published
29 Jun 2026 12:41
Source
citybiz
GlobeNewswire Direct company coverage

NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer

NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new Chief Executive Officer and a member of its Board of Directors, effective July 1, 2026. Dr. Gupta, who has over two decades of leadership experience in biopharmaceuticals and global health, will focus on advancing

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 11:09
Source
GlobeNewswire
Stock Titan Direct company coverage

NovaBridge taps physician-executive Dr. Gupta as CEO July 1

NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new CEO and a board member, effective July 1, 2026. Dr. Gupta, a physician-executive with over two decades of experience, will focus on advancing key drug candidates, expanding the ophthalmology franchise, and building

Tone
Positive 72/100
Event
Market update
Published
29 Jun 2026 10:41
Source
Stock Titan
Stock Titan Direct company coverage

Leadership shake-up at NovaBridge (Nasdaq: NBP) as Srishti Gupta becomes CEO

NovaBridge Biosciences (Nasdaq: NBP) has announced a significant leadership transition, appointing Dr. Srishti Gupta as the new Chief Executive Officer and a member of the Board of Directors, effective July 1, 2026. She succeeds Xi-Yong (Sean) Fu, who will step down but remain as

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 10:41
Source
Stock Titan
TradingView Direct company coverage

Price to earnings forward of NovaBridge Biosciences – NASDAQ:NBP

This article provides financial information for NovaBridge Biosciences (NASDAQ: NBP), specifically focusing on its forward price-to-earnings ratio. The content indicates market and company data provided by various financial services. The article appears to be a stub or specific d

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 00:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of NovaBridge Biosciences – NASDAQ:NBP

This article displays the "Price to sales forward" financial metric for NovaBridge Biosciences (NASDAQ: NBP). It is a direct data display from TradingView, showing the period, value, change, and change percentage for this specific financial indicator. The page indicates that the

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 00:21
Source
TradingView
TradingView Direct company coverage

NovaBridge Biosciences Sponsored ADR Actuals & Estimates (NASDAQ:NBP)

This page provides access to financial actuals and analyst estimates for NovaBridge Biosciences (NASDAQ:NBP). Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 14:10
Source
TradingView
Stock Titan Direct company coverage

NovaBridge Biosciences (NBP) grants options and RSUs to executive

NovaBridge Biosciences (NBP) has granted new equity awards to its Chief Business Development Officer, Cao Sean Wuxiong. The awards include 181,290 employee share options with an exercise price of $1.53 per ADS, vesting only when the 30-trading-day weighted average ADS price reach

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 23:39
Source
Stock Titan
Investing.com Direct company coverage

NovaBridge Biosciences CMO Dennis Andrew sells $5,606 in shares

NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, sold 8,494 ordinary shares (represented by 3,693 ADSs) for a total of $5,606 on June 18, 2026. This transaction occurred after an acquisition of 23,695 ordinary shares (10,302 ADSs) on June 17, 2026, and also i

Tone
Negative 42/100
Event
Deals and strategy
Published
23 Jun 2026 11:40
Source
Investing.com
Stock Titan Direct company coverage

NovaBridge Biosciences (NBP) CMO sells shares while exercising RSUs

NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, recently engaged in insider transactions, selling 8,494 Ordinary Shares at $0.66 each and exercising derivative awards for 10,302 Ordinary Shares represented by American Depositary Shares (ADSs). Following thes

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:40
Source
Stock Titan